<DOC>
	<DOCNO>NCT01318499</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Nepafenac Ophthalmic Suspension , 0.3 % prevention treatment inflammation ( swell redness ) pain eye cataract extraction .</brief_summary>
	<brief_title>Nepafenac 0.3 % Two Study</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>Planned cataract extraction phacoemulsification implantation posterior chamber intraocular lens ; Patients , opinion Investigator , would improvement bestcorrected visual acuity surgery ; Able understand sign inform consent ; Other protocoldefined inclusion criterion may apply . Use topical ocular , inhaled systemic nonsteroidal antiinflammatory drug within 7 day surgery , exception allow low dose aspirin ( 100 mg ) prior surgery study exit ; Use topical ocular , inhaled systemic steroid within 14 day prior surgery study exit ; History chronic recurrent inflammatory eye disease ( eg , iritis , scleritis , uveitis , iridocyclitis , rubeosis iridis ) operative eye ; Diabetic retinopathy operative eye ; Known suspect allergy hypersensitivity nonsteroidal antiinflammatory drug ( NSAIDs ) , component test article ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>cataract</keyword>
	<keyword>inflammation</keyword>
	<keyword>pain</keyword>
	<keyword>inflammatory cell</keyword>
	<keyword>aqueous flare</keyword>
</DOC>